Idiopathic pulmonary fibrosis

Thorax

Volumn 67, Issue 8, 2012, Pages 742-746

  Hoo, Zhe Hui ^a   Whyte, Moira K B ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GELSOLIN; SMALL INTERFERING RNA; ZINC FINGER PROTEIN;

APOPTOSIS; DISEASE COURSE; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FIBROGENESIS; FIBROSING ALVEOLITIS; GAS EXCHANGE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERSTITIAL LUNG DISEASE; LIFE EXPECTANCY; LUNG ALVEOLUS EPITHELIUM; LUNG BLOOD FLOW; LUNG CANCER; LUNG COMPLIANCE; LUNG FIBROBLAST; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW;

EID: 84864017304     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2011-200515     Document Type: Article

References (70)

1. Gribbin J, Hubbard RB, Le Jeune I, et al. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 2006;61:980-5. (Pubitemid 44787169)
2. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001;134:136-51. (Pubitemid 32096342)
3. Myers JL, Katzenstein AL. Epithelial necrosis and alveolar collapse in the pathogenesis of usual interstitial pneumonia. Chest 1988;94:1309-11. (Pubitemid 19002811)
4. Visscher DW, Myers JL. Histologic spectrum of idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006;3:322-9. (Pubitemid 43845409)
5. Nicholson AG, Fulford LG, Colby TV, et al. The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2002;166:173-7. (Pubitemid 34765453)
6. Harari S, Caminati A. IPF: new insight on pathogenesis and treatment. Allergy 2010;65:537-53.
7. Hinz B, Phan SH, Thannickal VJ, et al. The myofibroblast: one function, multiple origins. Am J Pathol 2007;170:1807-16. (Pubitemid 47339255)
8. Ohta K, Mortenson RL, Clark RA, et al. Immunohistochemical identification and characterization of smooth muscle-like cells in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1995;152:1659-65.
9. Chambers RC. Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention? Br J Pharmacol 2008;153(Suppl 1):S367-78. (Pubitemid 351340998)
10. Tliba O, Panettieri RA Jr. Regulation of inflammation by airway smooth muscle. Curr Allergy Asthma Rep 2008;8:262-8.
11. Hunninghake GW, Kawanami O, Ferrans VJ, et al. Characterization of the inflammatory and immune effector cells in the lung parenchyma of patients with interstitial lung disease. Am Rev Respir Dis 1981;123:407-12. (Pubitemid 11105708)
12. Crystal RG, Bitterman PB, Rennard SI, et al. Interstitial lung diseases of unknown cause. Disorders characterized by chronic inflammation of the lower respiratory tract. N Engl J Med 1984;310:235-44. (Pubitemid 14221962)
13. Kinder BW, Brown KK, Schwarz MI, et al. Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. Chest 2008;133:226-32.
14. Marchal-Somme J, Uzunhan Y, Marchand-Adam S, et al. Dendritic cells accumulate in human fibrotic interstitial lung disease. Am J Respir Crit Care Med 2007;176:1007-14. (Pubitemid 350127845)
15. Kuwano K, Hagimoto N, Kawasaki M, et al. Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis. J Clin Invest 1999;104:13-19. (Pubitemid 29534340)
16. Tzouvelekis A, Harokopos V, Paparountas T, et al. Comparative expression profiling in pulmonary fibrosis suggests a role of hypoxia-inducible factor-1alpha in disease pathogenesis. Am J Respir Crit Care Med 2007;176:1108-19. (Pubitemid 350223757)
17. Oikonomou N, Thanasopoulou A, Tzouvelekis A, et al. Gelsolin expression is necessary for the development of modelled pulmonary inflammation and fibrosis. Thorax 2009;64:467-75.
18. Whyte M. Gelsolin in idiopathic pulmonary fibrosis: a new target supports a central role for epithelial injury in disease pathogenesis. Thorax 2009;64:461-2.
19. Richter AG, McKeown S, Rathinam S, et al. Soluble endostatin is a novel inhibitor of epithelial repair in idiopathic pulmonary fibrosis. Thorax 2009;64:156-61.
20. Chilosi M, Poletti V, Zamo A, et al. Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol 2003;162:1495-502. (Pubitemid 36512831)
21. Plantier L, Crestani B, Wert SE, et al. Ectopic respiratory epithelial cell differentiation in bronchiolised distal airspaces in idiopathic pulmonary fibrosis. Thorax 2011;66:651-7.
22. Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 2011;364:1503-12.
23. Calabrese F, Lunardi F, Giacometti C, et al. Overexpression of squamous cell carcinoma antigen in idiopathic pulmonary fibrosis: clinicopathological correlations. Thorax 2008;63:795-802.
24. Park J, Kim DS, Shim TS, et al. Lung cancer in patients with idiopathic pulmonary fibrosis. Eur Respir J 2001;17:1216-19. (Pubitemid 32717481)
25. Aubry MC, Myers JL, Douglas WW, et al. Primary pulmonary carcinoma in patients with idiopathic pulmonary fibrosis. Mayo Clin Proc 2002;77:763-70. (Pubitemid 34847718)
26. Chapman HA, Allen CL, Stone OL. Abnormalities in pathways of alveolar fibrin turnover among patients with interstitial lung disease. Am Rev Respir Dis 1986;133:437-43. (Pubitemid 16126278)
27. Senoo T, Hattori N, Tanimoto T, et al. Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis. Thorax 2010;65:334-40.
28. Jayachandran A, Konigshoff M, Yu H, et al. SNAI transcription factors mediate epithelialemesenchymal transition in lung fibrosis. Thorax 2009;64:1053-61.
29. Lange-Sperandio B, Trautmann A, Eickelberg O, et al. Leukocytes induce epithelial to mesenchymal transition after unilateral ureteral obstruction in neonatal mice. Am J Pathol 2007;171:861-71. (Pubitemid 47440985)
30. Peinado H, Quintanilla M, Cano A. Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: mechanisms for epithelial mesenchymal transitions. J Biol Chem 2003;278:21113-23. (Pubitemid 36806424)
31. Borie R, Fabre A, Prost F, et al. Activation of somatostatin receptors attenuates pulmonary fibrosis. Thorax 2008;63:251-8. (Pubitemid 351373721)
32. Lebtahi R, Moreau S, Marchand-Adam S, et al. Increased uptake of 111In-octreotide in idiopathic pulmonary fibrosis. J Nucl Med 2006;47:1281-7. (Pubitemid 47544880)
33. Olias G, Viollet C, Kusserow H, et al. Regulation and function of somatostatin receptors. J Neurochem 2004;89:1057-91. (Pubitemid 38720193)
34. Konigshoff M, Dumitrascu R, Udalov S, et al. Increased expression of 5- hydroxytryptamin-2A/B receptors in idiopathic pulmonary fibrosis: a rationale for therapeutic intervention. Thorax 2010;65:949-55.
35. Berger M, Gray JA, Roth BL. The expanded biology of serotonin. Annu Rev Med 2009;60:355-66.
36. Fabre A, Marchal-Somme J, Marchand-Adam S, et al. Modulation of bleomycin-induced lung fibrosis by serotonin receptor antagonists in mice. Eur Respir J 2008;32:426-36.
37. Guignabert C, Izikki M, Tu LI, et al. Transgenic mice overexpressing the 5- hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circ Res 2006;98:1323-30. (Pubitemid 43948088)
38. Patel NM, Lederer DJ, Borczuk AC, et al. Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest 2007;132:998-1006.
39. Kinnula VL, Fattman CL, Tan RJ, et al. Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy. Am J Respir Crit Care Med 2005;172:417-22. (Pubitemid 41117386)
40. Borok Z, Buhl R, Grimes GJ, et al. Effect of glutathione aerosol on oxidanteantioxidant imbalance in idiopathic pulmonary fibrosis. Lancet 1991;338:215-16.
41. Behr J, Degenkolb B, Krombach F, et al. Intracellular glutathione and bronchoalveolar cells in fibrosing alveolitis: effects of N-acetylcysteine. Eur Respir J 2002;19:906-11. (Pubitemid 34567906)
42. Geiszt M. NADPH oxidases: new kids on the block. Cardiovasc Res 2006;71:289-99.
43. Mittal M, Roth M, Konig P, et al. Hypoxia-dependent regulation of nonphagocytic NADPH oxidase subunit NOX4 in the pulmonary vasculature. Circ Res 2007;101:258-67. (Pubitemid 47344075)
44. Cucoranu I, Clempus R, Dikalova A, et al. NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res 2005;97:900-7. (Pubitemid 41552675)
45. Amara N, Goven D, Prost F, et al. NOX4/NADPH oxidase expression is increased in pulmonary fibroblasts from patients with idiopathic pulmonary fibrosis and mediates TGFβ1-induced fibroblast differentiation into myofibroblasts. Thorax 2010;65:733-8.
46. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005;353:2229-42. (Pubitemid 41697286)
47. Knobloch J, Peters H, Jungck D, et al. TNFa-induced GM-CSF release from human airway smooth muscle cells depends on activation of an ET-1 autoregulatory positive feedback mechanism. Thorax 2009;64:1044-52.
48. Teder P, Noble PW. A cytokine reborn? Endothelin-1 in pulmonary inflammation and fibrosis. Am J Respir Cell Mol Biol 2000;23:7-10. (Pubitemid 30597089)
49. Corte TJ, Wort SJ, Wells AU. Pulmonary hypertension in idiopathic pulmonary fibrosis: a review. Sarcoidosis Vasc Diffuse Lung Dis 2009;26:7-19.
50. Richter AG, Stockley RA, Harper L, et al. Pulmonary infection in Wegener granulomatosis and idiopathic pulmonary fibrosis. Thorax 2009;64:692-7.
51. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;183:431-40.
52. Thabut G, Fournier M, Collard HR, et al. Prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2004;169:1075-6.
53. Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003;168:543-8. (Pubitemid 37088596)
54. Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003;168:531-7. (Pubitemid 37088594)
55. Collard HR, King TE Jr, Bartelson BB, et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168:538-42. (Pubitemid 37088595)
56. King TE Jr, Safrin S, Starko KM, et al. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest 2005;127:171-7. (Pubitemid 41724573)
57. Sumikawa H, Johkoh T, Colby TV, et al. Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival. Am J Respir Crit Care Med 2008;177:433-9. (Pubitemid 351317587)
58. Lynch DA, Godwin JD, Safrin S, et al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med 2005;172:488-93. (Pubitemid 41117395)
59. Corte TJ, Wells AU, Gatzoulis MA, et al. Non-invasive assessment of pulmonary blood flow using an inert gas rebreathing device in fibrotic lung disease. Thorax 2010;65:341-5.
60. Agusti AG, Roca J, Rodriguez-Roisin R, et al. Different patterns of gas exchange response to exercise in asbestosis and idiopathic pulmonary fibrosis. Eur Respir J 1988;1:510-16.
61. Flaherty KR, Andrei AC, Murray S, et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med 2006;174:803-9. (Pubitemid 44511662)
62. Lederer DJ, Arcasoy SM, Wilt JS, et al. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006;174:659-64. (Pubitemid 44395333)
63. Eaton T, Young P, Milne D, et al. Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005;171:1150-7. (Pubitemid 40663728)
64. Swigris JJ, Wamboldt FS, Behr J, et al. The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. Thorax 2010;65:173-7.
65. King TE Jr, Behr J, Brown KK, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008;177:75-81.
66. Holland AE, Hill CJ, Conron M, et al. Small changes in six-minute walk distance are important in diffuse parenchymal lung disease. Respir Med 2009;103:1430-5.
67. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med 1993;118:622-9. (Pubitemid 23102698)
68. Yorke J, Jones PW, Swigris JJ. Development and validity testing of an IPF-specific version of the St George's Respiratory Questionnaire. Thorax 2010;65:921-6.
69. Holland AE, Hill CJ, Conron M, et al. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax 2008;63:549-54. (Pubitemid 351831168)
70. Troosters T, Casaburi R, Gosselink R, et al. Pulmonary rehabilitation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:19-38. (Pubitemid 40923311)